Biotech | January 07, 2022
Merck KGaA to acquire biopharma CDMO Exelead for $780 million
The transaction is expected to close in the first quarter of 2022
The transaction is expected to close in the first quarter of 2022
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
A toll-free helpline to be set up to help doctors and patients
The glucometer connects to one’s smartphone and provides actionable diagnostic information
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
The product is expected to be available in a week’s time
It plans to deliver over 300 million doses to the Indian government
The company will market it under the brand name Molflu
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
Subscribe To Our Newsletter & Stay Updated
